TWST
Twist Bioscience Corporation
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$124.72
−3.10%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 431.8M | 376.6M | 313.0M | 245.1M | 203.6M |
| Cost of Revenue | 207.4M | 185.6M | 179.6M | 155.4M | 119.3M |
| Gross Profit | 224.4M | 191.0M | 133.3M | 89.7M | 84.2M |
| Operating Expenses | |||||
| R&D Expense | 71.9M | 80.3M | 90.9M | 106.9M | 120.3M |
| SG&A Expense | 290.3M | 247.0M | 218.4M | 189.7M | 212.9M |
| General & Admin Expense | 56.8M | 240.0M | — | 186.8M | — |
| Selling & Marketing Expense | 7.0M | 7.0M | — | 2.9M | — |
| Other Expenses | — | — | 44.9M | 10.3M | (14.2M) |
| Total Operating Expenses | 362.2M | 327.3M | 354.2M | 306.9M | 319.0M |
| Cost and Expenses | 569.6M | 512.8M | 533.8M | 462.3M | 438.3M |
| Operating Income (EBIT) | (137.8M) | (136.3M) | (220.8M) | (217.2M) | (234.8M) |
| Non-Operating | |||||
| Interest Income | 8.0M | 11.4M | 15.3M | 14.4M | 3.1M |
| Interest Expense | — | — | 29.0K | 5.0K | 80.0K |
| Net Interest Income | 8.0M | 11.4M | 15.3M | 14.4M | 3.0M |
| Other Non-Op Income/Expense | 1.9M | 59.3M | 12.7M | 13.7M | 6.5M |
| Non-Operating Income (excl Interest) | (4.6M) | (59.3M) | (12.7M) | (13.7M) | (6.6M) |
| EBT (Pre-Tax Income) | (135.9M) | (77.0M) | (208.2M) | (203.5M) | (228.3M) |
| Income Tax Expense | 241.0K | 719.0K | 560.0K | 1.2M | (10.4M) |
| Bottom Line | |||||
| Net Income | (136.7M) | (77.7M) | (208.7M) | (204.6M) | (217.9M) |
| Earnings from Cont. Ops | (136.1M) | (77.7M) | (208.7M) | (204.6M) | (217.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (136.7M) | (77.7M) | (208.7M) | (204.6M) | (217.9M) |
| Per Share | |||||
| Basic EPS | ($2.22) | ($1.30) | ($3.60) | ($3.60) | ($4.04) |
| Diluted EPS | ($2.22) | ($1.30) | ($3.60) | ($3.60) | ($4.04) |
| Revenue Per Share | $6.92 | $6.30 | $5.39 | $4.31 | $3.78 |
| Shares | |||||
| Basic Shares Outstanding | 62.4M | 59.8M | 58.0M | 56.9M | 53.9M |
| Diluted Shares Outstanding | 62.4M | 59.8M | 58.0M | 56.9M | 53.9M |
| Profitability Metrics | |||||
| EBITDA | (107.8M) | (52.1M) | (176.7M) | (174.2M) | (211.7M) |
| D&A | 25.4M | 24.9M | 31.4M | 29.3M | 16.5M |
| EBIT | (133.2M) | (77.0M) | (208.1M) | (203.5M) | (228.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026